Stay updated on Nivolumab vs Docetaxel in NSCLC: Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer site revision changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T22:40:20.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page remains a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T22:28:02.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page with the HTML shell (doctype and meta tags) and a 403 title, indicating the study page is currently inaccessible. A Home link and a revision note are displayed as part of the error page.
    Difference
    18%
    Check dated 2026-09-19T22:06:05.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Added 2015 ( U.S. NIH Grant/Contract ) attribution and updated the revision tag from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-29T21:52:18.000Z thumbnail image
  6. Check
    75 days ago
    Change Detected
    Summary
    Sponsor-specific recruitment and information sections were added, including 'BMS Clinical Trial Patient Recruiting' and 'BMS Clinical Trial Information.' The page now includes links to the Study Protocol PDF and other sponsor-provided resources, improving access to official trial documents and participation details.
    Difference
    66%
    Check dated 2026-08-08T16:45:39.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    Core study documentation and intervention details were removed from the record, including the Statistical Analysis Plan, Study Protocol, provided-by information, and drug names, along with related MeSH terms, affecting the transparency of the trial's design and materials.
    Difference
    17%
    Check dated 2026-08-01T14:01:25.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Docetaxel in NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.